Zobrazeno 1 - 10
of 277
pro vyhledávání: '"Drug Mechanisms"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nicole Kashani, Eve E. Kelland, Borna Vajdi, Lauren M. Anderson, Wendy Gilmore, Brett T. Lund
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis. It selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. We previously s
Externí odkaz:
https://doaj.org/article/a32c0f44f3e54f28a23b32a143d06001
Autor:
Derek L. Clouthier, Scott C. Lien, S. Y. Cindy Yang, Linh T. Nguyen, Venkata S. K. Manem, Diana Gray, Michael Ryczko, Albiruni R. A. Razak, Jeremy Lewin, Stephanie Lheureux, Ilaria Colombo, Philippe L. Bedard, David Cescon, Anna Spreafico, Marcus O. Butler, Aaron R. Hansen, Raymond W. Jang, Sangeet Ghai, Ilan Weinreb, Valentin Sotov, Ramy Gadalla, Babak Noamani, Mengdi Guo, Sawako Elston, Amanda Giesler, Sevan Hakgor, Haiyan Jiang, Tracy McGaha, David G. Brooks, Benjamin Haibe-Kains, Trevor J. Pugh, Pamela S. Ohashi, Lillian L. Siu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Immune checkpoint inhibitors (ICIs) demonstrate unprecedented efficacy in multiple malignancies; however, the mechanisms of sensitivity and resistance are poorly understood and predictive biomarkers are scarce. INSPIRE is a phase
Externí odkaz:
https://doaj.org/article/31ba8dd2f028423db6db252c1c7723fb
Autor:
Gerald Falchook, Jeffrey Infante, Hendrik-Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur Frankel, Peter Schmid, Kathleen Moore, William McCulloch, Katharine Grimmer, Marie O'Farrell, George Kemble, Howard Burris
Publikováno v:
EClinicalMedicine, Vol 34, Iss , Pp 100797- (2021)
Background: We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. Methods: This completed open-la
Externí odkaz:
https://doaj.org/article/2febb21dda0b44dcb8507b74f4dd5b16
Publikováno v:
eLife, Vol 9 (2020)
Doxycycline (DOX) is a key antimalarial drug thought to kill Plasmodium parasites by blocking protein translation in the essential apicoplast organelle. Clinical use is primarily limited to prophylaxis due to delayed second-cycle parasite death at 1
Externí odkaz:
https://doaj.org/article/c357fa8c47ce43b2acf3f9e12132fa51
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 1, p 141 (2019)
Oncogenic mutations in RAS genes result in the elevation of cellular active RAS protein levels and increased signal propagation through downstream pathways that drive tumor cell proliferation and survival. These gain-of-function mutations drive over
Externí odkaz:
https://doaj.org/article/864fc2aee6334aa185b16fe78cc1486e
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Alemtuzumab is a highly effective treatment for relapsing-remitting multiple sclerosis. It selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. We previously s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffad837f41265dec4377c15578a1cb38
https://pubmed.ncbi.nlm.nih.gov/34777337
https://pubmed.ncbi.nlm.nih.gov/34777337
Autor:
George Kemble, Natalie Cook, Kathleen N. Moore, Andrew Brenner, Jeffrey R. Infante, Shubham Pant, Emma Dean, Hendrik-Tobias Arkenau, Erkut Borazanci, Katharine Grimmer, Howard A. Burris, Manish R. Patel, Juanita Lopez, Gerald Steven Falchook, Peter Schmid, William McCulloch, Arthur E. Frankel, Marie O'Farrell
Publikováno v:
EClinicalMedicine
EClinicalMedicine, Vol 34, Iss, Pp 100797-(2021)
EClinicalMedicine, Vol 34, Iss, Pp 100797-(2021)
Background We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as monotherapy and with a taxane. Methods This completed open-labe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a9fa30ac7e81c6b6febf7918ef8d8b
https://pubmed.ncbi.nlm.nih.gov/33870151
https://pubmed.ncbi.nlm.nih.gov/33870151